FDA approved ado-trastuzumab emtansine (KADCYLA for injection, Genentech, Inc.),for use as a single agent for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either received prior therapy for metastatic disease or developed disease recurrence during or within six months of completing adjuvant therapy. February 22, 2013. More Information: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm340913.htm
| This email was sent to kostikblog@ukr.net using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
